CIGB-552 

CIGB-552 is a cell-penetrating peptide with anti-tumor properties with the IC₅₀ of 23 μM in H460 cells. CIGB-552 can increase the level of protein COMMD1. CIGB-552 significantly inhibits the NF-κB signaling pathway. CIGB-552 can promote apoptosis of the tumor cells. CIGB-552 can induce the accumulation of reactive oxygen species (ROS) in tumor cells. CIGB-552 has anti-inflammatory and anti-angiogenic effects. CIGB-552 can be used for the research of the lung cancer and colon cancer^[1][2][3][4].

CIGB-552 (20-60 μM, 5 h) can increase the protein content of the anti-tumor related protein COMMD1^[1].

CIGB-552 (25 μM, 0-12 h) promotes the ubiquitination degradation of RelA and inhibits NF-κB signaling in H460 cells^[1].

CIGB-552 (25 μM, 0-24 h) can increase the level of pro apoptotic proteins and reduce the level of anti apoptotic proteins in H460 cells^[1].

CIGB-552 (25 μM, 24-48 h) can induce apoptosis in lung cancer cells^[1].

CIGB-552 (25 μM, 8 h) reduces cellular antioxidant capacity, leading to protein and lipid oxidative damage in H460 cells ^[1].

CIGB-552 (37.5 μM, 1 h) induces the accumulation of reactive oxygen species (ROS) by inhibiting SOD1 activity, selectively killing tumor cells^[2].

CIGB-552 (75-150 μM, 24 h) can significantly inhibit TNF-α-induced NF-κB activation^[3].

CIGB-552 (2.5-25 μM, 24 h) exerts anti angiogenic effects by inhibiting hypoxia induced HIF-1 activation through COMMD1^[3].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

CIGB-552 (1 mg/kg; s.c.; three times a week; for three weeks) significantly inhibits tumor growth in the lung cancer miceand prolongs survival without causing significant toxicity^[2].
CIGB-552 (0.2-1.4 mg/kg; s.c.; two times a week; for two weeks) significantly inhibits tumor growth in mice with colon cancer and has anti angiogenic effects^[4].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

2689.21

C₁₃₁H₁₉₈N₃₈O₂₄

1630763-23-3

Solid

White to off-white

Ac-His-Ala-Arg-Ile-Lys-{d-Pro}-Thr-Phe-Arg-Arg-{d-Leu}-Lys-Trp-Lys-Tyr-Lys-Gly-Lys-Phe-Trp

Ac-HARIK-{d-Pro}-TFRR-{d-Leu}-KWKYKGKFW

Room temperature in continental US; may vary elsewhere.

Sealed storage, away from moisture

*In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)

* Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

* Note: If you choose water as the stock solution, please dilute it to the working solution, then filter and sterilize it with a 0.22 μm filter before use.

• [1]. Fernández Massó JR, et al. The Antitumor Peptide CIGB-552 Increases COMMD1 and Inhibits Growth of Human Lung Cancer Cells. J Amino Acids. 2013;2013:251398.  [Content Brief]

  [2]. Gomez Rodriguez Y, et al. Synergic effect of anticancer peptide CIGB-552 and Cisplatin in lung cancer models. Mol Biol Rep. 2022 Apr;49(4):3197-3212.  [Content Brief]

  [3]. Daghero H, et al. The Anticancer Peptide CIGB-552 Exerts Anti-Inflammatory and Anti-Angiogenic Effects through COMMD1. Molecules. 2020 Dec 31;26(1):152.  [Content Brief]

  [4]. Vallespí MG, et al. Antitumor efficacy, pharmacokinetic and biodistribution studies of the anticancer peptide CIGB-552 in mouse models. J Pept Sci. 2014 Nov;20(11):850-9.  [Content Brief]